GPDT Photodynamic Therapy: Oxford Researchers Shine Light on New Cancer Treatment

Last Updated on:

Oxford researchers from Oxperial BioHealth have revealed Green Products Photodynamic Therapy (GPDT), a groundbreaking innovation in cancer care. The therapy was unveiled at the 2024 Pharmaceutical Science Conference in Barcelona and the 20th Guangzhou International Symposium on Molecular Medicine, capturing significant global interest. Branded as “Sunshine Against Cancer,” GPDT represents a transformative leap in cancer treatment.

The team, led by Dr. Daniel T. H. Chen, Dr. Ta-Chun Liu, Pharmacist Shin-Yi Huang, and Dr. Yao-Kuan Chen, showcased how GPDT—a completely plant-based therapy—induces apoptosis (programmed cell death) in cancer cells, with the process amplified by sunlight. By utilising the therapeutic potential of plant chlorophyll and other natural compounds, GPDT provides a sustainable and minimally invasive alternative to conventional treatments.

GPDT is already patented in the UK and Taiwan, with international protections in progress. This innovative therapy disrupts tumour growth and differentiation, making it a groundbreaking development in oncology. By integrating sunlight with botanical compounds, GPDT offers an eco-friendly and forward-thinking solution to one of the world’s most pressing health concerns.

The international medical community has responded enthusiastically to this breakthrough, positioning GPDT as a potential turning point in the global fight against cancer. Could sunlight and nature hold the key to revolutionary cancer treatments? This innovation brings new hope.

Cancer continues to be the leading cause of death worldwide, yet GPDT offers promising possibilities. Speaking at the 2024 Barcelona Global Pharmacology Symposium, Dr. Daniel T. H. Chen detailed GPDT’s capabilities in targeting cancer cells. By combining sunlight exposure with natural plant compounds, this therapy operates at the cellular level to inhibit cancer cell growth.

The process harnesses the 400nm-700nm wavelength of sunlight to activate botanical components, generating reactive oxygen species such as single-state oxygen molecules. These molecules have shown significant anticancer properties in laboratory settings. GPDT presents a non-invasive and complementary option for those seeking alternative approaches to treatments known for their harsh side effects.

“GPDT is the world’s first natural photodynamic solution, combining sunlight and botanicals to offer a natural option for maintaining cellular balance and supporting overall health. By integrating outdoor sunlight exposure and plant-based dietary elements, individuals can pursue a more natural, holistic path to wellness,” explained Dr. Daniel Chen.

Looking ahead, Oxperial BioHealth has announced plans to launch PropoLight, the first GPDT product, in early 2025. PropoLight, a premium health supplement, is designed to promote cellular health and support overall wellness, particularly for individuals aiming to maintain long-term well-being.

Research partner Shin-Yi Huang revealed that PropoLight will undergo further certifications and clinical trials in both the UK and US to prepare for its pharmaceutical-grade iteration. This rigorous process will pave the way for its introduction to the global market.

PropoLight’s launch signifies an important step in merging natural health products with lifestyle-oriented wellness solutions. Oxperial BioHealth intends to broaden its offerings with advanced pharmaceutical-grade options, continuing to drive innovation in holistic health on a global scale.